These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 25815786

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT, Lu YY, An YX, Wang X, Zhao QC.
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y, Ying JM, Qiu T, Shan L, Guo L, Lü N.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.
    BMC Cancer; 2013 Apr 01; 13():169. PubMed ID: 23548132
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul 01; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

  • 13. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.
    Int J Clin Exp Pathol; 2014 Jul 01; 7(9):5927-39. PubMed ID: 25337237
    [Abstract] [Full Text] [Related]

  • 14. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
    Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M.
    Cytopathology; 2011 Dec 01; 22(6):358-64. PubMed ID: 21029218
    [Abstract] [Full Text] [Related]

  • 15. Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.
    Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G.
    PLoS One; 2012 Dec 01; 7(7):e41347. PubMed ID: 22911782
    [Abstract] [Full Text] [Related]

  • 16. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
    Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R, Capella G.
    Gut; 2013 Apr 01; 62(4):540-9. PubMed ID: 22798500
    [Abstract] [Full Text] [Related]

  • 17. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.
    Clin Chim Acta; 2012 Oct 09; 413(19-20):1605-11. PubMed ID: 22579930
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Oct 09; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 19. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.
    APMIS; 2013 Oct 09; 121(10):954-66. PubMed ID: 23992303
    [Abstract] [Full Text] [Related]

  • 20. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH.
    J Gastrointest Surg; 2009 Aug 09; 13(8):1510-6. PubMed ID: 19440799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.